Haemonetics Corporation

HAE Healthcare Medical Devices

Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025.

Revenue
+9.30%
EPS
+25.9%
Free cash flow
+20.4%
Total debt
+21.0%

Quarter to September 2026, against a year earlier

120.06 4.05 −3.26%
Market cap
$5.7B
P/E
54.5×
Fwd P/E
30.2×
Dividend yield
—
F-score
6/9
Altman Z
2.21
Beneish M
−2.81
Dividend safety
n/a
Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22 Mar '23 Mar '24 Mar '25 Mar '26
Piotroski F-Score
5 7 7 8 5 5 8 7 6 6
P/E ratio
0.00 83.91 85.48 66.00 71.16 75.26 36.78 37.03 19.03 27.76
Altman Z-Score
3.79 6.09 5.93 5.91 4.16 2.78 3.63 3.43 2.41 2.21
P/S ratio
2.36 4.21 4.78 5.11 6.46 3.25 3.60 3.28 2.35 1.99
Altman Z″-Score (non-manufacturers)
3.80 3.36 3.76 3.36 2.91 2.46 3.49 3.26 2.56 2.85
P/FCF ratio
24.19 25.67 107.23 40.02 76.47 41.49 50.42 29.56 19.30 10.16
Beneish M-Score
(3.20) (3.19) (2.73) (2.92) (2.57) (2.71) (2.73) (2.42) (2.64) (2.81)
P/Operating CF
60.45 66.06 224.11 108.86 3,637.28 47.42 52.79 67.09 27.44 37.48
P/B ratio
2.83 5.06 6.93 8.60 7.69 4.31 5.14 4.48 3.90 3.34
EV/Sales
2.49 4.08 4.94 5.28 7.04 3.55 4.00 3.76 2.80 2.72
EV/EBITDA
31.33 25.35 24.76 24.37 35.08 19.39 18.74 18.53 10.82 13.25
EV/FCF
25.51 24.85 110.78 41.35 83.24 45.35 56.06 33.82 23.01 13.88
Current Ratio
2.42 1.35 2.44 2.20 2.74 1.71 3.06 2.56 1.62 2.95
Net Debt/EBITDA
1.62 (0.83) 0.79 0.79 2.85 1.65 1.88 2.33 1.74 3.55
Debt/Equity
0.34 0.08 0.48 0.52 0.94 0.75 0.92 0.83 1.12 1.53
ROE
(3.60%) 6.11% 7.75% 12.20% 12.05% 5.86% 14.72% 13.22% 18.83% 12.03%
ROA
(2.05%) 3.68% 4.38% 6.02% 5.15% 2.36% 6.08% 5.69% 7.22% 4.02%
ROIC
(1.42%) 5.56% 6.36% 8.55% 4.56% 4.81% 7.57% 6.53% 9.66% 5.53%
Return on Tangible Assets
(4.22%) 9.72% 8.04% 13.14% 12.08% 7.58% 13.92% 15.07% 26.16% 11.34%
Average Days of Receivables
62.89 61.06 69.80 61.00 53.49 58.57 55.95 57.60 54.36 59.33
Earnings Yield
(1.23%) 1.19% 1.17% 1.52% 1.41% 1.33% 2.72% 2.70% 5.26% 3.60%
Free Cash Flow Yield
4.13% 3.90% 0.93% 2.50% 1.31% 2.41% 1.98% 3.38% 5.18% 9.85%
Free Cash Flow per Share
1.68 2.81 0.84 2.49 1.45 1.52 1.64 2.87 3.29 5.55
Book value per Share
14.35 14.26 12.96 11.58 14.43 14.68 16.11 18.93 16.31 16.88
Free Cash Flow
86.43 148.31 43.13 126.23 73.58 77.78 83.34 145.44 165.70 261.82
EV/EBIT
0.00 65.64 57.19 50.51 68.25 43.68 29.94 29.83 17.19 23.18
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026